Share Prices & Company Research

Market News

12 Mar 2021 | 11:28

Novavax Covid-19 vaccine more effective than previously thought

(Sharecast News) - The Covid-19 vaccine developed by Novavax demonstrated a higher efficacy than previously estimated against the mild, moderate and severe symptoms that the illness can bring on, final analysis of the late-stage trial conducted in the UK showed. Novavax's efficacy in that trial was pegged at 96.4%.

Significantly, the results of a separate trial conducted in South Africa revealed that it was 55.4% effective against the new and more troublesome strain of Covid-19 that is now dominant in South Africa.

Those results compared to previous efficacy estimates of 89.3% and 49.4%, respectively.

By 1138 GMT, shares of Novavax had leapt by 20.21% in pre-market trading in the US to reach $225.55.

Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.